)
)
Oncolytics Biotech Investor Relations Material
Latest events
Q3 2024
Oncolytics Biotech
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Oncolytics Biotech Inc
Access all reports
Oncolytics Biotech Inc. (Oncolytics) is a development-stage biopharmaceutical company. The company focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Oncolytics' research and development activities are based on its proprietary lipid nanoparticle-laden virus, REOLYSIN. REOLYSIN is developed under Oncolytics' strategic alliance with BioCity Group Pty Ltd, an Australian government-backed translational research group focused on the improvement of cancer care via clinical and pharma applications for regenerative medicines. Oncolytics also has a license agreement with DaktariPharma UAB, a Lithuanian drug discovery company specializing in use of alternative medicine to treat cancer, for use of the oral formulation of cyclopamine in several European markets including Germany, France and Italy.
Latest articles
)
Mercado Libre: The Digital Backbone of Latin America
From shopping to logistics and fintech, Mercado Libre is shaping the digital transformation of Latin America.
3 Jan 2025
)
House of Pinault: The History and Business of Kering and Gucci
Kering is a luxury group under the Pinault family's leadership, managing iconic brands like Gucci, Saint Laurent, and Bottega Veneta.
19 Dec 2024
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Ticker symbol
ONCY
Country
🇺🇸 United States